GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
Phase 1
Recruiting
- Conditions
- Renal Cell CarcinomaColorectal CancerHead and Neck CancerMalignant MelanomaBreast CancerCervical Cancer
- Interventions
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- GeneMedicine Co., Ltd.
- Target Recruit Count
- 125
- Registration Number
- NCT06265025
- Locations
- π°π·
National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of
π°π·Korea University Anam Hospital, Seoul, Korea, Republic of
π°π·Hanyang University Seoul Hospital, Seoul, Korea, Republic of